No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 31 of the 31 quarters in the window, leaving 0 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 37.8x · 10Y median 57.7x · 23rd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 32
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:58:06.246Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for NRx Pharmaceuticals, Inc. (NRXP) stock was $2.97 as of Oct 6, 2026, 3:55 PM EDT, up 3.31% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -12.2% · 3-year avg +1.4%/yr · 5-year avg -49.6%/yr
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases.
Biotechnology · Wilmington, DE
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-0.26
Revenue Est.
$1.22M
Last Quarter Results
EPS
$-0.24
vs Estimate
$-0.13
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NRXP | $128.37M | $2.96 | +3.31% | -12.18% | -49.61% | N/A | N/A |
| 2PYXS | $127.66M | $2.02 | -10.04% | -12.78% | N/A | N/A | vs NRXP |
| 3HCAT | $130.79M | $1.77 | +0.57% | -40.39% | -48.35% | N/A | vs NRXP |
| 4AIRS | $130.86M | $1.85 | -2.88% | -75.16% | N/A | N/A | vs NRXP |
| 5ENTX | $125.44M | $2.54 | -2.86% | +37.68% | -10.57% | N/A | vs NRXP |
| 6LFMD | $131.30M | $2.71 | -0.18% | -60.80% | -14.66% | +7.66% | vs NRXP |
forward FY estimate
N/A
$1.10M
vs Estimate
$1.33M
Consensus Rating
Based on 4 analysts
Average Price Target
$38.50
+1198.5% upside
Low
$10.00
Current
$2.96
High
$50.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.35 | $-0.21 | $-0.07 | 1 |
| Quarter ending Dec 2026 | $-0.43 | $-0.23 | $-0.03 | 1 |
| Quarter ending Mar 2027 | $-0.28 | $-0.16 | $-0.05 | 1 |
| Quarter ending Jun 2027 | $-0.21 | $-0.12 | $-0.04 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.42 | $-0.87 | $-0.57 | 2 |
| FY 2027 | $-0.67 | $-0.41 | $-0.27 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $487466.00 | $1.22M | $1.95M | 2 |
| Quarter ending Dec 2026 | $1.25M | $2.57M | $3.89M | 2 |
| Quarter ending Mar 2027 | $6.82M | $14.10M | $22.07M | 1 |
| Quarter ending Jun 2027 | $16.34M | $33.80M | $52.90M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.72M | $5.51M | $8.30M | 3 |
| FY 2027 | $55.77M | $90.17M | $124.56M | 3 |
